Inspira Technologies (Nasdaq:INN) announced today that it signed an exclusive OEM agreement with Terumo Cardiovascular.
In a news release, Inspira called Terumo Cardiovascular “experts” in oxygenation systems, heart-lung machines and monitoring systems. The agreement covers the manufacture of a flow mechanism for integration into Inspira’s products. The company designed these products for use in the extracorporeal circulation of blood during oxygenation.
The agreement may extend to integration into the Inspira ART system for acute respiratory care. ART boosts oxygen saturation levels in minutes using small volumes of blood. Inspira designed it to treat patients while awake and breathing spontaneously. This reduces the need for invasive mechanical ventilation.
“This is a very important agreement for the company, and we believe that it is in line with our strategy towards developing collaborations with the largest medical device companies to join in on our journey to market,” said Joe Hayon, Inspira co-founder and president.
Terumo Cardiovascular represents a division of Terumo Corporation. Terumo operates in more than 160 countries and regions across the globe. It provides over 50,000 products and services to patients in a variety of medical settings.
